Clinical trials: in Kyrgyzstan
Opioid Use Disorder
Expanding Medication-Assisted Therapies in Central Asia
Central Asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (PWID) and their sexual partners, and scaling up opioid agonist therapies (OAT) in this region is the…
- Trial name
- ExMAT CA (NCT05579470)
- Testing
- NIATx
- Where
- 4 sites in United States, Kazakhstan and 2 more
- Volunteers
- 900 people
- Sponsor
- Yale University
Chronic Migraine Headache
CHROnic Migraine Embolization
To evaluate the effectiveness and safety of middle meningeal artery (MMA) embolization using non-adhesive materials SQUID 12 and SQUID 18 as a treatment method for patients with chronic resistant migraine.
- Trial name
- CHROME (NCT06848166)
- Testing
- liquid embolic agent SQUID 12, liquid embolic agent SQUID 18
- Where
- Kyrgyzstan
- Volunteers
- 30 people
- Sponsor
- Vedanta University Clinic
COPD (Chronic Obstructive Pulmonary Disease)
Effect of Rehabilitation on the Respiratory Signal in Patients With COPD and Exercise-Induced Desaturation
The aim is to study the effect of SSOT during a 3-week in-patient pulmonary rehabilitation programme. Further aim is to analyse exercise endurance, distinguishing between those exercising whilst breathing air at 760m "normoxia"…
- Trial name
- NCT07107828
- Testing
- Ambient air, Oxygen, Altitude
- Where
- Kyrgyzstan
- Volunteers
- 52 people
- Sponsor
- Eastern Switzerland University of Applied Sciences
COPD
Effect of Rehabilitation at Moderate Altitude on Airway Resistance Measured With Forced Oscillation Technique in COPD-patients
Airway resistance will be measured using the forced oscillation technique (FOT). The parameters Rrs, Xrs, and ∆Xrs will be compared before and after a pulmonary rehabilitation cycle at moderate altitude.
- Trial name
- NCT07063563
- Testing
- ambiant air, Oxygen
- Where
- 2 sites in Kyrgyzstan, Switzerland
- Volunteers
- 52 people
- Sponsor
- Eastern Switzerland University of Applied Sciences
Hiv, Opioid Use
PRIDE III Prison Interventions and HIV Prevention Collaboration
The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a…
- Trial name
- PRIDE III (NCT06962033)
- Testing
- Opioid Agonist Therapy
- Where
- 5 sites in United States, Georgia and 3 more
- Volunteers
- 300 people
- Sponsor
- Yale University
COPD
Oxygen Therapy During Exercise Training in Inpatient Rehabilitation in Chronic Lung Disease- Does it Matter?
The aim of the current study is the effect of SSOT during a 3-weeks inpatient pulmonary rehabilitation program. Further aim is to analyze exercise endurance, distinguishing between those exercising whilst breathing air at 760m…
- Trial name
- NCT07044843
- Testing
- Oxygen, Standard ambiant air will be breathed during endurance training.
- Where
- 2 sites in Kyrgyzstan, Switzerland
- Volunteers
- 54 people
- Sponsor
- Eastern Switzerland University of Applied Sciences
Parent-Child Relationships, Child Maltreatment
Integrating Evidence-based Approaches to Prevent Child Maltreatment in Kyrgyzstan
The goal of this clinical trial is to learn if a family-based prevention program works to prevent child maltreatment risk and other adverse childhood experiences (ACEs) among families in Kyrgyzstan.
- Trial name
- NCT07712822
- Testing
- Integrated Family and Economic Empowerment Program
- Where
- Kyrgyzstan
- Volunteers
- 396 people, healthy volunteers welcome
- Sponsor
- The University of Texas at Arlington
Acute Mountain Sickness
HighCycle Study: Effect of High Altitude on Acute Mountain Sickness in Women Related to Their Menstrual Cycle Phase
Prospective cohort study investigating the menstrual cycle phase (MCP)-dependent incidence of acute mountain sickness (AMS) in women travelling to 3600 m.
- Trial name
- NCT06499714
- Testing
- Exposure to 3600 m
- Where
- Kyrgyzstan
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Zurich
High Altitude
HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men
Randomized clinical trial evaluating the effect of acetazolamide on pulmonary artery pressure in women compared to men travelling to 3600 m.
- Trial name
- NCT06498505
- Testing
- Acetazolamide
- Where
- Kyrgyzstan
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Sleep-Disordered Breathing
HighCycle Study: Effect of High Altitude on Sleep Disordered Breathing in Women Related to Their Menstrual Cycle Phase
Prospective cohort study investigating the menstrual cycle phase (MCP) dependent sleep disordered breathing (SDB) in women travelling to 3600 m.
- Trial name
- NCT06498544
- Testing
- Exposure to 3600 m
- Where
- Kyrgyzstan
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Sleep-Disordered Breathing
HighCycle Study: Effect of Acetazolamide on Sleep Disordered Breathing in Women Compared to Men
Randomized clinical trial evaluating the effect of acetazolamide on sleep disordered breathing in women compared to men travelling to 3600 m.
- Trial name
- NCT06498531
- Testing
- Acetazolamide
- Where
- Kyrgyzstan
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Stigma, Social, Drug Abuse Illicit
Lower Intersecting HIV-related Stigmas to Facilitate Treatment as Prevention (LIFT)
The purpose of this study is to reduce HIV transmission risk among people who inject drugs (PWID) through a multilevel intervention known as LIFT.
- Conditions
- Stigma, Social, Drug Abuse Illicit, HIV (Human Immunodeficiency Virus)
- Trial name
- LIFT (NCT07541131)
- Testing
- LIFT for People Who Use Drugs, LIFT for MMT Providers
- Where
- Kyrgyzstan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Acute Mountain Sickness
HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men
Millions of people travel to high altitude for work or leisure activities and are exposed to reduced inspiratory oxygen partial pressure and hypoxemia that may lead to altitude illness, among which the most common form is acute…
- Trial name
- NCT06499727
- Testing
- Acetazolamide
- Where
- Kyrgyzstan
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), 6MWT Assessed at High Altitude (3200m) vs Low Altitude (760m)
To study the effect of relocation from 3200m (Aksay) to 760m (Bishkek) in highlanders with High Altitude Pulmonary Hypertension (HAPH) who permanently live >2500m on 6-minute walk distance (6MWD)
- Trial name
- NCT06489691
- Testing
- 6-minute walk test (6MWT)
- Where
- Kyrgyzstan
- Volunteers
- 24 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), SDB Assessed at HA (3200 m) vs LA (760 m)
To study the effect of relocation from 3200m (Aksay) to 760m (Bishkek) in highlanders with High Altitude Pulmonary Hypertension (HAPH) who permanently live >2500m on sleep disordered breathing
- Trial name
- NCT06489717
- Testing
- SDB assessment
- Where
- Kyrgyzstan
- Volunteers
- 24 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
Highlanders With High Altitude Pulmonary Hypertension (HAPH), 6 Minute Walk Distance (6MWD) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)
The investigators aim to study the effect of SOT in highlanders with high altitude pulmonary hypertension (HAPH) who permanently live >2500m on 6-minute walk distance (6MWD) assessed at 3200m.
- Trial name
- NCT06489743
- Testing
- 6-minute walk test (6MWT)
- Where
- Kyrgyzstan
- Volunteers
- 24 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)
To study the effect of relocation from 3200 m (Aksay) to 760 m (Bishkek) in patients with high altitude pulmonary hypertension (HAPH) who permanently live >2500 m on pulmonary artery pressure (PAP)
- Trial name
- NCT06489704
- Testing
- Echocardiography
- Where
- Kyrgyzstan
- Volunteers
- 24 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)
The investigators aim to study the effect of SOT in highlanders with high altitude pulmonary hypertension (HAPH) who permanently live >2500m on pulmonary arterial pressure (PAP) assessed at 3200 m.
- Trial name
- NCT06489756
- Testing
- Echocardiography
- Where
- Kyrgyzstan
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Respiratory Tract Infection Bacterial, Respiratory Tract Infection Viral
CRP and Patient Information Leaflets to Optimise Antibiotic Treatments for Adults With Respiratory Tract Infections in Primary Care in Kyrgyzstan
This study aims to determine how CRP levels and Patient Information Leaflets (PILs) affect antibiotic prescribing in adults with acute respiratory symptoms in Kyrgyz primary care.
- Conditions
- Respiratory Tract Infection Bacterial, Respiratory Tract Infection Viral, AMR, CRP
- Trial name
- 2CARE INSTALL (NCT07261969)
- Testing
- The C-reactive protein point-of-care test (CRP-POCT), Patient information leaflets
- Where
- 2 sites in Kyrgyzstan
- Volunteers
- 1,050 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Alveolar Echinococcosis
Treatment Trial of Alveolar Echinococcosis
A new focus of subjects with lesions of alveolar echinococcosis caused by Echinococcus multilocularis has been found south of Gulcha in Osh province in Kyrgyzstan by an ultrasound surveillance.
- Trial name
- NCT07182305
- Testing
- Efficacy of albendazole for early stage intervention of alveolar echinococcosis
- Where
- Kyrgyzstan
- Volunteers
- 194 people
- Sponsor
- Ministry of Health, Kyrgyzstan